1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Novavax’s Jn.1-Adapted COVID-19 Vaccine Granted FDA Emergency Use Authorisation

04 Sep 2024
Admin
News Article

Novavax’s Jn.1-Adapted COVID-19 Vaccine Granted FDA Emergency Use Authorisation

Overview

Novavax’s JN.1-adapted COVID-19 vaccine has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) for use in individuals aged 12 years and older.

About JN.1

The announcement comes just over a week after the regulator approved updated vaccines from Pfizer/BioNTech and Moderna that target the KP.2 strain, a descendant of JN.1.
JN.1 only accounts for 0.2% of cases across the country, according to the latest Centers for Disease Control and Prevention data, but is the ‘parent strain’ of currently circulating variants.

Recent Guidance from the FDA

The adaptations are based on recent guidance from the FDA, which advised COVID-19 vaccine manufacturers in June that vaccines for 2024/2025 should target JN.1, particularly KP.2 “if feasible”.
Its latest authorisation was supported by non-clinical data that showed Novavax’s updated vaccine provides cross-reactivity against JN.1 and multiple JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.

From Center for Biologics Evaluation and Research

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said: “COVID-19 continues to be a very real risk for many people, and we encourage individuals to consider getting an updated COVID-19 vaccine when eligible.
“[This] authorisation provides an additional COVID-19 vaccine option that meets the FDA’s standards for safety, effectiveness and manufacturing quality needed to support EUA.”

Syringes Availability

Pre-filled syringes of the vaccine will be available in thousands of locations following the Center for Biologics Evaluation and Research’s release of vaccine batches, Novavax said.

Words from the CEO: Novavax

The company’s president and chief executive officer, John Jacobs, said: “[This] authorisation enables Novavax to launch our updated COVID-19 vaccine in the US in pre-filled syringes, and we have worked hard to ensure consumers have access in thousands of locations nationwide.”

Annual cpmposition review- The FDA has previously outlined that it anticipates that the composition of COVID-19 vaccines will need to be evaluated annually, as occurs for seasonal influenza vaccines.

Pfizer/BioNTech and Moderna have been developing combination vaccines for flu and COVID-19.

Previous Results

Top-line results from a late-stage study of Pfizer and BioNTech’s candidate were announced last month.
Moderna also recently shared positive phase 3 results for its own flu/COVID-19 combination vaccine candidate and said it will “engage with regulators on next steps”.